Fig. 6From: Quality of life in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: a systematic review and meta-analysisIn global QLQ-C30, subgroup analysis (open-label trials versus double-blind trials) was performed on the mean difference within the PD-1/PD-L1 inhibitors group (A), within the chemotherapy group (B), and between the PD-1/PD-L1 inhibitors group and chemotherapy group (C) according to the maskingBack to article page